Healthcare law company Frier Levitt has analyzed FDA enforcement steps from “investigation only” peptide distributors. Their summary: the FDA considers an item’s classification based upon its intended use, not its disclaimers. When Internet websites include things like dosage guides, reconstitution Directions, or connection to message boards